GlassScriptPhysician profile
Diana Mannschreck
NPI 1235595166
$9,534.23
in general payments reported to CMS, 2019-2025
25 companies · $4,389 in 2025
The $4,389 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2023: $537 · 2024: $4,499 · 2025: $4,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,967 · Education: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,967.37 |
| Education | $457.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $1,453.42 | 2024-2025 | Daxxify, Daxi |
| Sun Pharmaceutical Industries INC. | $847.32 | 2023-2025 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $831.20 | 2024-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $746.95 | 2023-2025 | |
| Genzyme Corporation | $703.65 | 2023-2025 | |
| Lilly USA, LLC | $645.64 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $546.45 | 2023-2025 | Dupixent |
| Incyte Corporation | $539.41 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $437.78 | 2024-2025 | |
| Amgen INC. | $430.78 | 2023-2025 | Otezla, Otezla |
| Leo Pharma INC. | $386.23 | 2024-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $304.54 | 2023-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $275.18 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $244.28 | 2023-2025 | Nemluvio, Aklief, Twyneo |
| Almirall LLC | $217.48 | 2024-2025 | Seysara, Klisyri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $216.22 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $150.80 | 2024-2025 | Jublia, Cabtreo, Arazlo |
| Stemline Therapeutics INC. | $109.80 | 2021 | |
| Mayne Pharma Commercial LLC | $107.78 | 2025 | |
| Pfizer INC. | $92.48 | 2023-2024 | |
| Ucb, INC. | $85.43 | 2024-2025 | Bimzelx |
| Organon LLC | $85.05 | 2025 | Vtama |
| Botanix Sb INC | $35.30 | 2025 | Sofdra |
| Journey Medical Corporation | $21.91 | 2024 | |
| Fidia Pharma USA INC. | $19.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Mannschreck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.